Exelixis, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael Morrissey
- Full Time Employees
- 1,077
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1851 Harbor Bay Parkway Alameda CA United States of America 94502
- IPO Date
- Apr 17, 2000
- CIK
- 0000939767
- Website
- exelixis.com
- Similar Companies
- Business
- Exelixis, Inc. (Nasdaq: EXEL) is an oncology-focused biotechnology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers. The company offers CABOMETYX (cabozantinib) tablets for advanced renal cell carcinoma, hepatocellular carcinoma, and previously treated advanced neuroendocrine tumors; COMETRIQ (cabozantinib) capsules for metastatic medullary thyroid cancer; and COTELLIC (cobimetinib), partnered with Roche/Genentech for advanced melanoma. Exelixis advances a diversified pipeline of small-molecule therapeutics and biotherapeutics, including bispecific antibodies, antibody-drug conjugates, next-generation kinase inhibitors such as zanzalintinib in phase 3 trials for renal cell carcinoma, hepatocellular carcinoma, and squamous cell carcinoma of the head and neck, and early-stage programs like XL309 targeting PARP inhibitors. Founded in 1994 and headquartered in Alameda, California, the company conducts global operations through strategic partnerships with Bristol Myers Squibb, Merck, Takeda Pharmaceutical, and others to expand development and commercialization reach. Recent developments include U.S. FDA approval of a new CABOMETYX indication for previously treated advanced neuroendocrine tumors; authorization of a $500 million stock repurchase program in February 2025 following completion of a prior $500 million program from August 2024, with over $1.2 billion returned to shareholders since March 2023; plans to initiate phase 3 trials for zanzalintinib in neuroendocrine tumors and two Merck-collaborated renal cell carcinoma studies in 2025; and ongoing enrollment in XL309 monotherapy and combination trials for PARP-refractory tumors.
Company News
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
Strong Sales, Earnings Send Exelixis Shares Higher
Allworth Financial LP Takes Position in Exelixis, Inc. $EXEL
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
Here's Why Exelixis (EXEL) is a Strong Value Stock
Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky
Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Exelixis (EXEL)
EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)
EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis
Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)
Arkadios Wealth Advisors Purchases New Position in Exelixis, Inc. $EXEL